Jason Cota & William “Barry” Inman – Advanced Infectious Disease Pharmacology Course

Keywords List

And

and

the

of

for

to

For

is

you

a

Summary

• Jason Cota & William “Barry” Inman – Advanced Infectious Disease Pharmacology CourseIn the new world where COVID-19 is taking center stage, having solid infectious disease pharmacology knowledge is essential for your patient care.If you don’t know the core principles, how can you identify when something is new, different or strange?

• And missing a key finding in a patient can be the difference between a treated infection and sepsis.Let two infectious disease experts sharpen your skills…This carefully curated online course covers proper prescribing, patient education, and monitoring procedures for a variety of drug regimens used to treat common acute and chronic infectious diseases.Jason and Barry not only teach the foundations of infectious disease pharmacology, but ground them in real-life experiences…“Jason had a great mix of technical biochemical info and meds with the practical day-to-day use of this info.” — Karen M, NP“Loved [Barry’s] incorporation of personal and work experience!” — Joy L, RNPLUS, get special bonus content on COVID-19 vaccines and treatments!This self-paced video training will give you the skills to:Confidently select the best empiric therapy before culture data is availableNarrow antibiotic coverage at the right time like a seasoned proExpertly reduce bacterial resistance — your colleagues will think you wrote the IDSA guidelines!Interpret culture and sensitivity results to select the most narrow and targeted antibiotic therapyEarn up to 16.25 CE hours – INCLUDING up to 7.3 pharmacology CE hours… And so much more!Here’s what you’ll cover in this state-of-the-art online training course:Pharmacology of Infectious Diseases & Immunizations for Advanced Practice Clinicians— with Jason Cota, PharmD, MSAntimicrobialsDrug classesPharmacokinetic PropertiesConcentration-dependent killingTime-dependent killingPost-antibiotic effectCommon interactions with other drugsAntibacterial Allergies — Sulfa and PenicillinDefine true allergySulfonamide antibiotics vs non-antibioticsPenicillin — Cephalosporin cross-sensitivityBacteriaDifferentiationNormal floraCommon pathogensAntibacterial Resistance — Contributing FactorsTrendsMechanisms of resistanceContributing factorsMethicillin-Resistant Staphylococcus Aureus — Community versus Hospital AcquiredDifferentiating between CA- and HA-MRSACurrent clinical practice guidelinesPharmacologic managementEnterobacteriaceae ResistanceExtended Spectrum Beta-Lactamase (ESBL)What are ESBLsPharmacologic managementCarbapenem-Resistant Enterobacteriaceae (CRE)What are CREsPharmacologic managementUrinary Tract InfectionsBacterial Etiology, Signs and Symptoms and DiagnosisCystitis and pyelonephritisComplicated and uncomplicatedUTIs in pregnancyTreatment (IDSA Guideline Treatment Algorithm)AcuteRecurrent and relapseClostridium Difficile InfectionRisk factorsPharmacology managementFecal TransplantationProbiotics literature reviewCommunity-Acquired PneumoniaBacterial etiologyDiagnosisTypical vs.

• MRSASigns & symptomsTreatment (IDSA Guidelines)InfluenzaClinical featuresDiagnosisPharmacology managementImmunizations (Adult)Types of VaccinesGeneral recommendationsContraindications & precautionsInfection Control Challenges: Real Risks for Patients and Staff— with William “Barry” Inman, BA-BS, CICA Summary of Current Recommendations From the CDC, SHEA, IDSA, APIC and the Joint CommissionHealth-Care Associated Infections: Strategies to Control-Reduce-EliminateCatheter-Associated Urinary Tract InfectionsSurgical Site InfectionsVentilator-Associated PneumoniasNon-ventilator Associated Infections (overlooked HAI)Central-Line Associated Bloodstream InfectionsThe Latest Multi-Drug Resistant Microorganism GuidelinesCarbapenem-resistant enterobacteriaceaeClostridium difficileMethicillin-resistant staphylococcus aureusVancomycin resistant enterococcusAcinetobacter baumanniiInfluenzaAvian vs.

• seasonal influenzaH1N1 pandemic resultsWhen to treat?

• When not to treat?Treatment with anti-virals and antibioticsNew vaccines for fluVaccination Recommendations for Healthcare PersonnelZoster/shinglesPneumoccocalMMR, Tdap, etc.Emerging Infectious Diseases (Zoonotic)Ebola: What we learnedMosquito-borne (“Zika”, Dengue, Chickungunya, West Nile)Tick-borne (Lyme and Babesia)CryptosporidiosisBloodborne PathogensHepatitis B Vaccination protocol for healthcare personnelStaff follow-up after significant exposuresTreatments for persons chronically infectedOutbreaks in healthcareHepatitis C Treatment “cures” in 12-24 weeksOutbreaks in healthcare-dialysis settingsHIV/AIDS New one pill daily treatmentHealthcare exposure and appropriate prophylaxisTuberculosisToday’s best approaches to treatmentSkin testing vs.